
Jacqueline W. Miller, MD1, Judith Lee Smith, PhD1, A. Blythe Ryerson, PhD, MPH1, Thomas C. Tucker, PhD, MPH2, and Claudia Allemani, MSc, PhD, FHEA, HonMFPH3

1Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
2Kentucky Cancer Registry, University of Kentucky, Lexington, Kentucky
3Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom

Abstract

BACKGROUND—Reducing breast cancer incidence and achieving equity in breast cancer outcomes remains a priority for public health practitioners, health care providers, policy makers, and health advocates. Monitoring breast cancer survival can help evaluate the effectiveness of health services, quantify inequities in outcomes between states or population subgroups, and inform efforts to improve the effectiveness of cancer management and treatment.

METHODS—We analyzed breast cancer survival using individual patient records from 37 statewide registries that participated in the CONCORD-2 study, covering approximately 80% of the US population. Females were diagnosed between 2001 and 2009 and were followed through December 31, 2009. Age-standardized net survival at 1 year, 3 years, and 5 years after diagnosis was estimated by state, race (white, black), stage at diagnosis, and calendar period (2001–2003 and 2004–2009).

RESULTS—Overall, 5-year breast cancer net survival was very high (88.2%). Survival remained remarkably high from 2001 through 2009. Between 2001 and 2003, survival was 89.1% for white females and 76.9% for black females. Between 2004 and 2009, survival was 89.6% for white females and 78.4% for black females.
CONCLUSIONS—Breast cancer survival was more than 10 percentage points lower for black females than for white females, and this difference persisted over time. Reducing racial disparities in survival remains a challenge that requires broad, coordinated efforts at the federal, state, and local levels. Monitoring trends in breast cancer survival can highlight populations in need of improved cancer management and treatment.

Keywords
breast cancer; health disparities; population-based survival; trends

INTRODUCTION

The burden of breast cancer has been a persistent concern among public health practitioners, health care providers, policy makers, and health advocates. Worldwide, breast cancer is the second most common cancer and the fifth leading cause of cancer deaths among females. In the United States, breast cancer is the most commonly diagnosed cancer (excluding skin cancer) and the second leading cause of cancer deaths among females. Since early 2004, breast cancer incidence has been stable, whereas breast cancer mortality has been decreasing. However, these trends have not been equal among all populations.

The elimination of health disparities is a goal of many federal agencies. For example, the US. Department of Health and Human Services, the Agency for Healthcare Research and Quality, and the Centers for Disease Control and Prevention (CDC) have developed action plans to reduce health disparities.

Unequal incidence of advanced-stage breast cancer, receipt of high-quality treatment, and breast cancer death rates have not changed much over time. Breast cancer incidence rates have historically been higher among white females, while mortality rates have been higher among black females. The annual average percentage change in incidence from 1999 through 2013 varied by race, with a 0.8% decrease per year among white females and a 0.4% increase per year among black females. Breast cancer mortality rates have fallen since the mid-1990s to 2012 among both black and white females, but the rate of decline has been faster among white females (annual percentage change, −1.9% vs −1.5%). Although there have been great advancements in treatment options, racial inequalities in breast cancer survival in the United States still persist.

An evaluation of population-based survival trends can help to inform cancer-control efforts by identifying opportunities for improvement in early detection, diagnosis, and treatment. Population-based survival is a key measure of the effectiveness of cancer management and treatment. Black females are more often diagnosed with regional or late-stage disease and have higher death rates than white females, regardless of stage. In 2008, the CONCORD study reported 5-year population-based survival in 31 countries, including 22 registries in 16 US states. Five-year survival in North America was among the highest in the world at 84%, with large survival differences between white (84.7%) and black (70.9%) females in the United States, suggesting that black females may not have the same access to and quality of care as white females. The second cycle of the CONCORD program (CONDORD-2) examined survival from 10 common cancers in 67 countries. CONCORD-2 is the largest study of population-based cancer survival trends to date, evaluating trends in 5-year survival.
for over 25 million individual patients diagnosed during the 15 years between 1995 and 2009. Age-standardized, 5-year net survival from breast cancer increased in many countries worldwide. In the United States, it rose from 86% between 1995 and 1999 to 88.6% between 2005 and 2009.

This report describes trends in net survival in a population-based setting (ie, the survival for all females with breast cancer) after controlling for competing risks of death. Net survival allows us to estimate and compare survival for females with breast cancer between countries or states without using the cause of death, which is often unreliable or not comparable between different states. By using the US data from CONCORD-2, we examined the distribution of breast cancer stage at diagnosis by race, state, and over time. We also analyzed survival trends by race, stage, and state. This study provides information on the effectiveness of the US health system in managing females with breast cancer from diagnosis to the final outcome. This analysis is part of the largest population-based study of cancer survival trends in the United States, including over 10 million patients with cancer.

**MATERIALS AND METHODS**

**Data**

We used data from 37 state cancer registries funded by either the CDC’s National Program of Cancer Registries (NPCR), the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, or both. These registries participated in the CONCORD-2 study, which covered approximately 80% of the US population. Registries consented to the inclusion of their data in the more detailed analyses reported here. We analyzed individual tumor records for 1,372,377 females (ages 15–99 years) who were diagnosed with breast cancer (International Classification of Diseases for Oncology, third edition, codes C50.0-C50.6 and C50.8-C50.9) between 2001 and 2009 and were followed until December 31, 2009. We included primary invasive cancers of the breast, regardless of whether the woman had a previous cancer. If a woman was diagnosed with ≥2 cancers of the breast between 2001 and 2009, then only the first was considered in the survival analyses. All races were included in the study, but we only reported separate survival for blacks and whites because of the small numbers for the other races in many states. Females who were excluded from the data were those who were registered from a death certificate only, were lost to follow-up, had inconsistent site-morphology combinations, or had invalid dates.

Patients were grouped by year of diagnosis into 2 calendar periods (2001–2003 and 2004–2009) to reflect changes in the methods used by US registries to collect data on stage at diagnosis. From 2001, most registries coded stage directly from the source data to SEER Summary Stage 2000 (SS2000). From 2004, all registries began to derive SS2000 using the Collaborative Stage unified data collection system.

**Survival Analyses**

We estimated net survival up to 5 years after diagnosis and 95% confidence intervals (CIs) using the Pohar Perme estimator. We analyzed survival by race, stage at diagnosis, calendar period of diagnosis, and US state. Net survival is the probability of surviving up to
a given time since diagnosis, after controlling for other causes of death (background mortality). In other words, it is the probability that females with breast cancer will survive their cancer. The certified cause of death and the cause coded as the underlying cause of death are often unreliable or not comparable between different states. The risk of death from causes other than the breast cancer (competing risks of death, or background mortality) also varies widely between populations and over time. To control for the wide differences in background mortality among participating states while estimating net survival, we constructed life tables of all-cause mortality in the general population of each state from the number of deaths and the population, by single year of age, sex, calendar year, and, where possible, by race (black, white), using a flexible Poisson model. Methods for constructing the life tables have been published.

We estimated net survival using the cohort approach for females diagnosed between 2001 and 2003, because they all had been followed for at least 5 years by December 31, 2009. We used the complete approach to estimate net survival for females diagnosed between 2004 and 2009, because 5 years of follow-up data were not available for all females. Net survival was estimated for 5 age-groups (ages 15–44, 45–54, 55–64, 65–74, and 75–99 years). We obtained age-standardized survival estimates using the International Cancer Survival Standard weights. If 2 or more of the 5 age-specific estimates could not be obtained, then we present only the pooled, unstandardized survival estimate for all ages combined. Trends, geographic variations, and differences in age-standardized survival by race are presented graphically in bar charts and funnel plots. More details on data and methods are provided in an accompanying article.

RESULTS

There were 1,372,377 US females (85.1% white females and 10.4% black females) diagnosed with breast cancer in participating registries between 2001 and 2009. Overall, there were no substantial changes in SEER Summary Stage distribution between the 2001 through 2003 and 2004 through 2009 periods (Table 1). Between 2001 and 2003, most breast cancers were diagnosed at local stage (60%), approximately 30% were regional stage, and <5% were distant stage. The proportion of females with unknown stage was low at 7%. The distribution remained similar between 2004 and 2009, exhibiting a slight reduction in the percentage of cancers of unknown stage cancer. The stage distribution varied slightly between states (Supporting Table 1). During both calendar periods of diagnosis, a lower proportion of black females were diagnosed at local stage, and the proportion of distant stage was about 1.6 times that of white females.

Survival decreased with time after diagnosis. Survival at 3 years was lower than at 1 year after diagnosis, and survival at 5 years was lower than at 3 years after diagnosis in both time periods (Table 2). Between 2001 and 2003, breast cancer 5-year net survival for all races combined was high at 88.2%, and it remained high at 88.6% between 2004 and 2009. Overall, the difference in 5-year survival between black females and white females was greater than 10 percentage points between 2001 and 2003, and this disparity did not decrease over time. Between 2004 and 2009, survival varied widely between states (range, 85.4%–92.4%), and it was systematically lower for black females (Supporting Table 2).
Five-year net survival was high for females who were diagnosed with local stage cancer between 2001 and 2003 at 98% and remained high for those who were diagnosed between 2004 and 2009 (Table 3). In both periods, the difference in survival between white females and black females was highest for those with regional tumors (82.3% and 83.5%, respectively, for white females vs 69.9% and 71.8%, respectively, for black females) and distant tumors (22.5% and 25.7%, respectively, for white females vs 15.2% and 17.1%, respectively, for black females). This difference was noticed in all states and did not decrease over time (Supporting Table 3). For local stage, the racial disparity persisted but to a smaller extent (98.2% and 98.6%, respectively, for white females vs 92.8% and 94.3%, respectively, for black females).

Figure 1 illustrates 5-year age-standardized net survival by state. Between 2001 and 2003, 5-year survival for breast cancer was very high at approximately 90%. Survival remained high between 2004 and 2009, with slight variation between states and regions. There was a 0.5% increase in net survival across the United States. The change in survival among states ranged from −2.9% to 3.6%.

Figure 2 provides funnel plots of net survival for the periods 2001 through 2003 and 2004 through 2009 to provide further insight into the variability of breast cancer survival in the United States by race and state. The plots reveal how much a particular survival estimate deviates from the pooled US value (the “target,” represented in the plot by the horizontal line) given the precision of each estimate. These plots indicate striking geographic and racial variation in survival. Between 2001 and 2003, net survival was lower for black females in all states. Although survival for black females increased slightly between 2004 and 2009, it remained lower for black females compared with white females in most states. Also in most states, survival for white females was above the pooled US estimate, whereas survival for all black females was below the pooled US estimate.

**DISCUSSION**

The current study is the largest study to date on trends in population-based breast cancer survival in the United States. It is also unique, in that the data are analyzed by race, stage at diagnosis, and state. This expands the US results from CONCORD-2 by providing a detailed analysis of net survival by race and stage at diagnosis. Population-based survival is a key measure of the overall effectiveness of the health system in dealing with cancer and thus is a useful measure for evaluating access to and quality of care and appropriate treatment. These results can be used to plan future cancer-control strategies.

Overall survival for breast cancer was strikingly high between 2001 and 2003 and remained high between 2004 and 2009. There was wide variability in survival between states, with lower survival for black than for white females in all 37 states included in the analyses. Disappointingly, the greater than 10% difference in survival between white and black females did not improve over time. More efforts need to be initiated to understand the reasons for this persistent racial disparity in breast cancer survival and to help black females in accessing early diagnosis and appropriate treatment.
Black/white inequalities in survival suggest differences in access to care and in tumor morphology between the groups. Within the same stage of disease, net survival is lower among black females. However, black/white differences in mammography rates by state are not consistent with stage of disease or survival. Indeed, there were no significant state-specific differences between black and white females who reported having had a mammogram within the past 2 years during the study periods.\textsuperscript{27}

**Clinical Perspective**

Having access to diagnostic studies and high-quality treatment is important for improving breast cancer survival. Black females are more likely than white females to experience delays in treatment and not to receive appropriate treatment for breast cancer.\textsuperscript{28} Delays in care and inappropriate treatment can result in larger tumors and poorer outcomes. Timely follow-up of abnormal test results and receipt of treatment after diagnosis could improve outcomes of all females with breast cancer.\textsuperscript{29} Access to quality care is a key factor to reducing disparities in breast cancer survival.

Breast cancer is a very heterogeneous disease. There are several different types of breast cancer with multiple subtypes based on biomarkers, such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor status. Differences in tumor morphology not only dictate treatment but also are prognostic. For example, triple-negative breast cancer (a breast cancer subtype that does not have estrogen receptor, progesterone receptor, or HER2 protein) is a more aggressive tumor with lower survival and is diagnosed more often among black females.\textsuperscript{30,31} There may be other tumor characteristics or underlying biologic differences between black and white females impacting tumor progression or therapy response that could be contributing to the observed survival differences by race.

Research is continually identifying new tumor bio-markers that have potential for use in a clinical setting. As treatment becomes more individualized, not all options are always available to all patients. Therefore, as newer treatments improve survival, it may not improve survival equally among all females. If minority or low-income females do not have access to newer treatment options, then survival improvements may not be as apparent among these groups in population-based surveillance systems. This may be 1 reason why we see that, at the same stage of diagnosis, net survival is lower among black than among white females.

**Cancer-Control Perspective**

In addition to addressing potential racial differences in the clinical care for breast cancer to reduce racial breast cancer survival disparities, there are several health behavior factors that can reduce the risk for breast cancer.\textsuperscript{32–35} Modifying risk factors, such as obesity, lack of physical activity, alcohol consumption, exposure to environmental toxins, and use of hormone therapy, can reduce a woman’s risk of getting breast cancer. Black females often have more comorbid conditions, which put them at greater risk for poorer survival outcomes. \textsuperscript{36} Women who may be at high risk for breast cancer because of family history or genetic reasons may need enhanced screening and risk-reduction procedures, such as taking antiestrogens or undergoing prophylactic mastectomy. Minority and low-income females
more often have limited access to these options, which ultimately may put them at increased risk of dying from breast cancer.

Once diagnosed with breast cancer, females need to be educated and empowered to take part in treatment decisions and to receive timely, guideline-concordant, and complete treatment. Females who have lack of trust in the health care system or who are characterized by cultural differences from their health care providers may not receive the needed treatment and supportive care. Studies that analyzed the availability of equal treatment among all patients demonstrated that patients have similar outcomes when they receive equal treatment. This suggests that the large and persistent survival deficit in black females between 2001 and 2009 may be attributable to the receipt of less effective treatment. Supportive care is also an area that needs more attention. Specifically, interventions to address geographic isolation, cultural differences, financial burden, and fear may be needed to improve access to quality care. These issues may be addressed along with clinical care.

**Strengths and Limitations**

This is the largest study comparing breast cancer survival by state and race using data from CONCORD-2, which include high-quality data covering greater than 80% of the US population. In addition, for females diagnosed with breast cancer, 98.9% of cases were morphologically verified, and the percentage of cases with unknown stage was low. All participating registries were certified by the North American Association of Central Cancer Registries as having met data quality and completeness standards (available at: http://www.naaccr.org/Certification/Criteria.aspx, Accessed June 28, 2017).

The current study had a few limitations. First, the follow-up procedures in the United States differed according to the federal funding source. All SEER registries are required to conduct follow-up of all cases to ascertain vital status. NPCR registries are only funded to ascertain deaths through linkage with the state vital records and the National Death Index. Some state cancer registries assumed that a patient was alive if the case was not included on a state death certificate database or on the National Death Index. Second, the manner in which SEER SS2000 data were collected and reported changed for all registries in 2004, as described above (see Methods). This resulted in a decrease in the percentage of cases with unknown stage when stage was derived rather than manually coded. Next, the states in the Western Region (Mountain and Pacific Divisions) had too few black females to reliably assess racial differences, and some states did not report stage data, which could result in the data not being generalizable to the entire United States. Further, we were only able to report on black and white women due to low numbers of other races in most states. Finally, vital status follow-up data were only available through December 31, 2009; therefore, we did not have 5-year follow-up for each patient. Because the remarkable differences between black and white females have persisted for more than a decade in this study, they are unlikely to simply disappear with the inclusion of more recent years of follow-up data. The third cycle of the CONCORD program is ongoing, and the data set is currently being updated. This will include patients who were diagnosed and followed until the end of 2014.
Conclusion

There is increasing awareness and effort to achieve health equity among racial, ethnic, geographic, socioeconomic, and other groups. With the persistent disparity in breast cancer survival between black females and white females, more national, local, and individual efforts are needed. This study provides accurate, useful information on incidence and survival of breast cancer patients in various US subpopulations and is supported through a nation-wide system of central cancer registries funded by the CDC’s NPCR or the National Cancer Institute’s SEER program.45

The CDC and its partners are dedicated to identifying and addressing the factors that lead to health disparities among racial, ethnic, geographic, socioeconomic, and other groups so that barriers to health equity can be removed. The CDC’s National Breast and Cervical Cancer Early Detection Program works with the states, tribes/tribal organizations, and territories to provide assistance to low-income females to ensure that they have access to appropriate breast and cervical cancer screening, diagnostic, and treatment services.45 The CDC’s Comprehensive Cancer Control Program works with states, tribes/tribal programs, and territories to develop cancer-control plans that focus on prevention, screening, and survivorship issues.45 Working with partner organizations, such as the National African American Tobacco Prevention Network and the National Alliance for Hispanic Health, these programs target specific populations who are at risk of developing or dying from cancer.

Eliminating or reducing disparities in breast cancer survival will require broad, coordinated population efforts at various federal, state, and local levels. The persistent black/white disparities in breast cancer survival reported here demonstrate that increased focus on individual, provider, community, organizational, and policy levels are warranted. Public health has an important opportunity to expand outreach to medically underserved females, provide education about breast cancer risk reduction, and increase awareness about post-treatment strategies to improve outcomes. Evidence-based interventions to further improve provider awareness, knowledge, and practice also need to be identified. Finally, public health professionals can champion community-level engagement and partnerships to leverage organizational infrastructure and provide evidence to inform organizational policies that ensure equal cancer care among all females and a reduction in breast cancer survival disparities. Focusing on education and informed decisions, cultural sensitivities, personalized care, and equal access to care are critical steps.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

FUNDING SUPPORT

Funding support for Claudia Allemani: US Centers for Disease Control and Prevention (CDC:12FED03123, ACO12036).
References


Figure 1.
Breast cancer 5-year age-standardized net survival (%) is illustrated for females (ages 15–99 years) diagnosed 2001–2003 and 2004–2009 along with absolute changes (%). States are grouped by US Census region. Note that data from 37 statewide cancer registries (covering 80.6% of the population) are ranked within US Census region by the survival estimate for 2004–2009. Dark bars denote states funded by the Centers for Disease Control and Prevention National Program of Cancer Registries; pale bars, states funded by the National Cancer Institute’s Surveillance, Epidemiology and End Results Program. Asterisks indicate states that are funded by both federal surveillance programs. Change (%) was not plotted if a survival estimate was not available for 1 calendar period or if 1 or more estimates were not age standardized.
Breast cancer 5-year age-standardized net survival (%) is illustrated for females (ages 15–99 years) by state, race, and calendar period of diagnosis. Note that the pooled US survival estimate for each calendar period is indicated by the solid horizontal line with corresponding 95.0% and 99.8% control limits (dashed lines).

**Figure 2.**
TABLE 1


<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>446,106</td>
<td>385,888</td>
<td>42,401</td>
<td>926,271</td>
<td>782,220</td>
<td>100,611</td>
</tr>
<tr>
<td>Local, %</td>
<td>59.1</td>
<td>60.5</td>
<td>47.5</td>
<td>59.1</td>
<td>60.5</td>
<td>48.5</td>
</tr>
<tr>
<td>Regional, %</td>
<td>29.8</td>
<td>29.1</td>
<td>35.3</td>
<td>30.2</td>
<td>29.6</td>
<td>35.2</td>
</tr>
<tr>
<td>Distant, %</td>
<td>4.4</td>
<td>4.2</td>
<td>6.8</td>
<td>5.2</td>
<td>4.9</td>
<td>7.8</td>
</tr>
<tr>
<td>Unknown, %</td>
<td>6.7</td>
<td>6.2</td>
<td>10.3</td>
<td>5.4</td>
<td>5.0</td>
<td>8.4</td>
</tr>
</tbody>
</table>

Abbreviation: SEER, Surveillance, Epidemiology, and End Results.
## TABLE 2

Breast Cancer: Age-Standardized Net Survival (%) at 1 Year, 3 Years, and 5 Years for Females (Ages 15–99 Years) Diagnosed Between 2001 and 2009, by Race and Calendar Period of Diagnosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Races</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>NS (%)</td>
<td>95% CI</td>
</tr>
<tr>
<td>1</td>
<td>96.5</td>
<td>96.4–96.6</td>
</tr>
<tr>
<td>3</td>
<td>91.8</td>
<td>91.6–91.9</td>
</tr>
<tr>
<td>5</td>
<td>88.2</td>
<td>88.0–88.3</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; NS, net survival.
## TABLE 3

Breast Cancer: 5-Year Age-Standardized Net Survival (%) for Females (Ages 15–99 Years) Diagnosed Between 2001–2009, by SEER Summary Stage 2000 at Diagnosis, Race, and Calendar Period of Diagnosis

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NS (%)</td>
<td>95% CI</td>
<td>NS (%)</td>
<td>95% CI</td>
<td>NS (%)</td>
<td>95% CI</td>
</tr>
<tr>
<td>All stages</td>
<td>88.2</td>
<td>88.0–88.3</td>
<td>89.1</td>
<td>88.9–89.3</td>
<td>76.9</td>
<td>76.2–77.6</td>
</tr>
<tr>
<td>Local</td>
<td>98.0</td>
<td>97.8–98.2</td>
<td>98.2</td>
<td>98.0–98.4</td>
<td>92.8</td>
<td>91.9–93.7</td>
</tr>
<tr>
<td>Regional</td>
<td>81.2</td>
<td>80.8–81.6</td>
<td>82.3</td>
<td>82.0–82.7</td>
<td>69.9</td>
<td>68.5–71.2</td>
</tr>
<tr>
<td>Distant</td>
<td>21.5</td>
<td>20.9–22.2</td>
<td>22.5</td>
<td>21.7–23.2</td>
<td>15.2</td>
<td>13.6–16.9</td>
</tr>
<tr>
<td>Unknown</td>
<td>72.5</td>
<td>71.8–73.2</td>
<td>73.1</td>
<td>72.4–73.9</td>
<td>65.9</td>
<td>63.8–67.9</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; NS, net survival; SEER, Surveillance, Epidemiology, and End Results.